A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis

Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: cddfff5bc1c3cef5e095e73293e6116f9b284b76
First added on: Feb 06, 2025